beta

ALDX

Aldeyra Therapeutics Inc.

Aldx

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-14-2018 08-09-2018 05-15-2018 03-29-2018 11-09-2017 08-08-2017 05-15-2017
Actual EPS -0.52 -0.46 -0.43 -0.37 -0.32 -0.35 -0.37
Consensus EPS -0.47 -0.39 -0.37 -0.32 -0.38 -0.37 -0.33
Estimated EPS -0.47 -0.39 -0.37 -0.32 -0.38 -0.37 -0.33
Number of Estimates 2 2 1 2 2 2 3
EPS Surprise -$0.05 -$0.07 -$0.06 -$0.05 $0.06 $0.02 -$0.04

Stats

Summary

Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.

Market Cap: 142 Million

Primary Exchange: NASDAQ Capital Market

Website: http://www.aldeyra.com

Shares Outstanding: 19.1 Million

Float: 18.8 Million

Dividend: 0.0 (0.0%)

Beta: 0.624496

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 375 Thousand

Ethical Flags

Animal testing

Longest drawdown: 920 trading days

From: 2015-01-30 To: 2018-09-25

Lowest Point:

Aldeyra Therapeutics: Multiple Readouts Ahead In 2019

via: SeekingAlpha at 2018-12-05 10:43:47:000

Shares of Aldeyra Therapeutics (ALDX) have gained only 10% since I initially brought this one to readers' attention in September of 2017. The stock has risen nearly 35% since my February post stated it had several reasons to run higher as dry eye data loomed. In the interest of full disclo… read more...

Aldeyra Therapeutics: Multiple Readouts Ahead In 2019

via: SeekingAlpha at 2018-12-05 10:43:47:000

Shares of Aldeyra Therapeutics (ALDX) have gained only 10% since I initially brought this one to readers' attention in September of 2017. The stock has risen nearly 35% since my February post stated it had several reasons to run higher as dry eye data loomed. In the interest of full disclo… read more...

Aldeyra Therapeutics: Multiple Readouts Ahead In 2019

via: SeekingAlpha at 2018-12-05 10:43:47:000

Shares of Aldeyra Therapeutics (ALDX) have gained only 10% since I initially brought this one to readers' attention in September of 2017. The stock has risen nearly 35% since my February post stated it had several reasons to run higher as dry eye data loomed. In the interest of full disclo… read more...

Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference

via: PR Newswire at 2018-11-28 08:00:00:000

LEXINGTON, Mass. , Nov.28, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M… read more...

Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference

via: PR Newswire at 2018-11-28 08:00:00:000

LEXINGTON, Mass. , Nov.28, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M… read more...

Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference

via: PR Newswire at 2018-11-28 08:00:00:000

LEXINGTON, Mass. , Nov.28, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M… read more...

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-14 11:32:07:000

Aldeyra Therapeutics, Inc. (ALDX) Q3 2018 Earnings Conference Call November 14, 2018 8:00 AM ET Executives Joshua Reed - Chief Financial Officer Todd Brady - Chief Executive Officer Analysts Neil Carnahan - Stifel Esther Hong - Janney Presentation Operator Good mo… read more...

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-14 11:32:07:000

Aldeyra Therapeutics, Inc. (ALDX) Q3 2018 Earnings Conference Call November 14, 2018 8:00 AM ET Executives Joshua Reed - Chief Financial Officer Todd Brady - Chief Executive Officer Analysts Neil Carnahan - Stifel Esther Hong - Janney Presentation Operator Good mo… read more...

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-14 11:32:07:000

Aldeyra Therapeutics, Inc. (ALDX) Q3 2018 Earnings Conference Call November 14, 2018 8:00 AM ET Executives Joshua Reed - Chief Financial Officer Todd Brady - Chief Executive Officer Analysts Neil Carnahan - Stifel Esther Hong - Janney Presentation Operator Good mo… read more...

Aldeyra Therapeutics net loss widens in Q3

via: SeekingAlpha at 2018-11-14 07:39:21:000

Aldeyra Therapeutics ( ALDX ) Q3 results : Revenues: $0; R&D Expense: $7.9M (+125.7%); SG&A: $3.1M (+106.7%); Net Loss: ($10.8M) (-116.0%); Loss Per Share: ($0.52) (-62.5%); Quick Assets: $7M. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Earnings news and comm… read more...

Aldeyra Therapeutics net loss widens in Q3

via: SeekingAlpha at 2018-11-14 07:39:21:000

Aldeyra Therapeutics ( ALDX ) Q3 results : Revenues: $0; R&D Expense: $7.9M (+125.7%); SG&A: $3.1M (+106.7%); Net Loss: ($10.8M) (-116.0%); Loss Per Share: ($0.52) (-62.5%); Quick Assets: $7M. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Earnings news and comm… read more...

Aldeyra Therapeutics net loss widens in Q3

via: SeekingAlpha at 2018-11-14 07:39:21:000

Aldeyra Therapeutics ( ALDX ) Q3 results : Revenues: $0; R&D Expense: $7.9M (+125.7%); SG&A: $3.1M (+106.7%); Net Loss: ($10.8M) (-116.0%); Loss Per Share: ($0.52) (-62.5%); Quick Assets: $7M. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Earnings news and comm… read more...

Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results

via: PR Newswire at 2018-11-14 07:00:00:000

LEXINGTON, Mass. , Nov. 14, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results … read more...

Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results

via: PR Newswire at 2018-11-14 07:00:00:000

LEXINGTON, Mass. , Nov. 14, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results … read more...

Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results

via: PR Newswire at 2018-11-14 07:00:00:000

LEXINGTON, Mass. , Nov. 14, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results … read more...

Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference

via: PR Newswire at 2018-11-06 08:00:00:000

LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M.D., Ph.D… read more...

Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference

via: PR Newswire at 2018-11-06 08:00:00:000

LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M.D., Ph.D… read more...

Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference

via: PR Newswire at 2018-11-06 08:00:00:000

LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M.D., Ph.D… read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2018 Financial Results

via: PR Newswire at 2018-11-05 08:00:00:000

LEXINGTON, Mass. , Nov. 5, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Wednesday, Novem… read more...

Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

via: PR Newswire at 2018-09-28 08:00:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M.D… read more...

Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

via: PR Newswire at 2018-09-28 08:00:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M.D… read more...

Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

via: PR Newswire at 2018-09-28 08:00:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M.D… read more...

Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

via: PR Newswire at 2018-09-28 08:00:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M.D… read more...

Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

via: PR Newswire at 2018-09-28 08:00:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M.D… read more...

Aldeyra Therapeutics prices common stock offering

via: SeekingAlpha at 2018-09-28 05:58:07:000

Aldeyra Therapeutics (NASDAQ: ALDX ) prices its public offering of 5.25M common shares at a price of $13.75 per share, for gross proceeds of ~$72.2M. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Aldeyra Therapeutics prices common stock offering

via: SeekingAlpha at 2018-09-28 05:58:07:000

Aldeyra Therapeutics (NASDAQ: ALDX ) prices its public offering of 5.25M common shares at a price of $13.75 per share, for gross proceeds of ~$72.2M. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Aldeyra Therapeutics prices common stock offering

via: SeekingAlpha at 2018-09-28 05:58:07:000

Aldeyra Therapeutics (NASDAQ: ALDX ) prices its public offering of 5.25M common shares at a price of $13.75 per share, for gross proceeds of ~$72.2M. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Aldeyra Therapeutics prices common stock offering

via: SeekingAlpha at 2018-09-28 05:58:07:000

Aldeyra Therapeutics (NASDAQ: ALDX ) prices its public offering of 5.25M common shares at a price of $13.75 per share, for gross proceeds of ~$72.2M. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Aldeyra Therapeutics prices common stock offering

via: SeekingAlpha at 2018-09-28 05:58:07:000

Aldeyra Therapeutics (NASDAQ: ALDX ) prices its public offering of 5.25M common shares at a price of $13.75 per share, for gross proceeds of ~$72.2M. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock

via: PR Newswire at 2018-09-27 20:00:00:000

LEXINGTON, Mass. , Sept. 27, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwr… read more...

Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock

via: PR Newswire at 2018-09-27 20:00:00:000

LEXINGTON, Mass. , Sept. 27, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwr… read more...

Your Daily Pharma Scoop: Reata Positive, Aldeyra Zooms, AstraZeneca Positive

via: SeekingAlpha at 2018-09-27 13:53:47:000

Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space, and also provide quick commentary on other im… read more...

Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

via: PR Newswire at 2018-09-26 16:01:00:000

LEXINGTON, Mass. , Sept. 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it intends to offer and s… read more...

Midday Gainers / Losers (09/26/2018)

via: SeekingAlpha at 2018-09-26 12:40:49:000

Gainers: ALDX +60% . VLRX +25% . IGC +23% . AGMH +21% . ELMD +21% . XOMA +13% . GWGH +13% . LQDA +13% . AVXL +14% . MMYT +12% . More news on: Aldeyra Therapeutics, Inc., Valeritas Holdings, Inc., India Globalization Capital, Inc, Stocks on the move, , Top s… read more...

Aldeyra +43%; Canaccord sees another 150% upside

via: SeekingAlpha at 2018-09-26 12:01:27:000

Calling this morning's data a "major positive," Canaccord slaps a Street-high price target of $35 on Aldeyra (NASDAQ: ALDX ). More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (09/26/2018)

via: SeekingAlpha at 2018-09-26 09:24:00:000

ALDX +28% on positive action in mid-stage dry eye study. More news on: Aldeyra Therapeutics, Inc., India Globalization Capital, Inc, Oasmia Pharmaceutical, Stocks on the move, , Top stock market news, Read more … read more...

Aldeyra's reproxalap shows positive action in mid-stage dry eye study; shares ahead 6% premarket

via: SeekingAlpha at 2018-09-26 07:23:16:000

Thinly traded micro cap Aldeyra Therapeutics (NASDAQ: ALDX ) is up 6% premarket on light volume on the heels of its announcement of positive results from a Phase 2b clinical trial evaluating topical ocular reproxalap in patients with dry eye disease. More news on: Aldeyra The… read more...

Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial

via: PR Newswire at 2018-09-26 07:00:00:000

LEXINGTON, Mass. , Sept. 26, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced positive results from its… read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Phase 2b Dry Eye Disease Clinical Trial

via: PR Newswire at 2018-09-25 16:30:00:000

LEXINGTON, Mass. , Sept. 25, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced it will hold a webcast an… read more...

Aldeyra's ganetespib shows positive effect in mesothelioma study; shares ahead 5% premarket

via: SeekingAlpha at 2018-09-25 09:17:24:000

Thinly traded micro cap Aldeyra Therapeutics (NASDAQ: ALDX ) is up 5% premarket on light volume on the heels of its announcement of positive data from a Phase 1/2 clinical trial, MESO-2, evaluating ADX-1612 (ganetespib), combined with pemetrexed and platinum-based chemo, in pat… read more...

Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer

via: PR Newswire at 2018-09-25 08:00:00:000

LEXINGTON, Mass. , Sept. 25, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Aldeyra) (NASDAQ: ALDX), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced positive top-line results from… read more...

Stocks To Watch: Calling Up Animal Spirits

via: SeekingAlpha at 2018-09-22 08:26:48:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The animal spirits of investors appear to be revving up, with the Dow Jones Industr… read more...

Stocks To Watch: Calling Up Animal Spirits

via: SeekingAlpha at 2018-09-22 08:26:48:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The animal spirits of investors appear to be revving up, with the Dow Jones Industr… read more...

Stocks To Watch: Calling Up Animal Spirits

via: SeekingAlpha at 2018-09-22 08:26:48:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The animal spirits of investors appear to be revving up, with the Dow Jones Industr… read more...

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 13:50:11:000

Aldeyra Therapeutics, Inc. (ALDX) Q2 2018 Earnings Conference Call August 09, 2018, 08:00 ET Executives Joshua Reed - CFO Todd Brady - CEO, President & Director Analysts Neil Carnahan - Stifel, Nicolaus & Company Elemer Piros - Cantor Fitzgerald & Co. I-Eh Je… read more...

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 13:50:11:000

Aldeyra Therapeutics, Inc. (ALDX) Q2 2018 Earnings Conference Call August 09, 2018, 08:00 ET Executives Joshua Reed - CFO Todd Brady - CEO, President & Director Analysts Neil Carnahan - Stifel, Nicolaus & Company Elemer Piros - Cantor Fitzgerald & Co. I-Eh Je… read more...

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 13:50:11:000

Aldeyra Therapeutics, Inc. (ALDX) Q2 2018 Earnings Conference Call August 09, 2018, 08:00 ET Executives Joshua Reed - CFO Todd Brady - CEO, President & Director Analysts Neil Carnahan - Stifel, Nicolaus & Company Elemer Piros - Cantor Fitzgerald & Co. I-Eh Je… read more...

Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-08-09 07:30:00:000

LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results f… read more...

Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-08-09 07:30:00:000

LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results f… read more...

Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-08-09 07:30:00:000

LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results f… read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2018 Financial Results and Corporate Update

via: PR Newswire at 2018-08-02 08:00:00:000

LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Thursday, August … read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2018 Financial Results and Corporate Update

via: PR Newswire at 2018-08-02 08:00:00:000

LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Thursday, August … read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2018 Financial Results and Corporate Update

via: PR Newswire at 2018-08-02 08:00:00:000

LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Thursday, August … read more...

Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference

via: PR Newswire at 2018-08-01 08:00:00:000

LEXINGTON, Mass. , Aug. 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady , M.D., Ph.D… read more...

Aldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer

via: PR Newswire at 2018-07-31 08:00:00:000

LEXINGTON, Mass. , July 31, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the appointment of Joshua… read more...

Aldeyra commences late-stage study of reproxalap in rare inherited skin disorder

via: SeekingAlpha at 2018-07-24 09:53:05:000

Enrollment is underway in a Phase 3 clinical trial evaluating Aldeyra Therapeutics' ( ALDX +0.6% ) topical dermal reproxalap for the treatment of ichthyosis (thickened, dry scaly skin) in patients with Sjgren-Larsson Syndrome (SLS). More news on: Aldeyra Therapeutics, Inc., He… read more...

Aldeyra commences late-stage study of reproxalap in rare inherited skin disorder

via: SeekingAlpha at 2018-07-24 09:53:05:000

Enrollment is underway in a Phase 3 clinical trial evaluating Aldeyra Therapeutics' ( ALDX +0.6% ) topical dermal reproxalap for the treatment of ichthyosis (thickened, dry scaly skin) in patients with Sjgren-Larsson Syndrome (SLS). More news on: Aldeyra Therapeutics, Inc., He… read more...

Aldeyra commences late-stage study of reproxalap in rare inherited skin disorder

via: SeekingAlpha at 2018-07-24 09:53:05:000

Enrollment is underway in a Phase 3 clinical trial evaluating Aldeyra Therapeutics' ( ALDX +0.6% ) topical dermal reproxalap for the treatment of ichthyosis (thickened, dry scaly skin) in patients with Sjgren-Larsson Syndrome (SLS). More news on: Aldeyra Therapeutics, Inc., He… read more...

Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial

via: PR Newswire at 2018-07-24 08:00:00:000

LEXINGTON, Mass. , July 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the first patient has enro… read more...

Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial

via: PR Newswire at 2018-07-24 08:00:00:000

LEXINGTON, Mass. , July 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the first patient has enro… read more...

Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial

via: PR Newswire at 2018-07-24 08:00:00:000

LEXINGTON, Mass. , July 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the first patient has enro… read more...

Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial

via: PR Newswire at 2018-07-12 08:00:00:000

LEXINGTON, Mass. , July 12, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced that the last patient has complet… read more...

Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial

via: PR Newswire at 2018-07-12 08:00:00:000

LEXINGTON, Mass. , July 12, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced that the last patient has complet… read more...

Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial

via: PR Newswire at 2018-07-12 08:00:00:000

LEXINGTON, Mass. , July 12, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced that the last patient has complet… read more...

Aldeyra Therapeutics Announces Development Programs at 2018 Research Day

via: PR Newswire at 2018-06-26 08:00:00:000

LEXINGTON, Mass. , June 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced product development programs in s… read more...

Aldeyra Therapeutics Announces Development Programs at 2018 Research Day

via: PR Newswire at 2018-06-26 08:00:00:000

LEXINGTON, Mass. , June 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced product development programs in s… read more...

Aldeyra Therapeutics Announces Development Programs at 2018 Research Day

via: PR Newswire at 2018-06-26 08:00:00:000

LEXINGTON, Mass. , June 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced product development programs in s… read more...

Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes

via: PR Newswire at 2018-06-25 16:01:00:000

LEXINGTON, Mass. , June 25, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the Company was added… read more...

Aldeyra Therapeutics Announces 2018 Research Day

via: PR Newswire at 2018-06-20 08:00:00:000

LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Resear… read more...

Aldeyra Therapeutics Announces 2018 Research Day

via: PR Newswire at 2018-06-20 08:00:00:000

LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Resear… read more...

Aldeyra Therapeutics Announces 2018 Research Day

via: PR Newswire at 2018-06-20 08:00:00:000

LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Resear… read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:10:50:000

Aldeyra Therapeutics, Inc. (ALDX) Q1 2018 Earnings Conference Call May 15, 2018 8:00 AM ET Executives Todd Brady - Chief Executive Officer of Aldeyra Therapeutics Steve Tulipano - Chief Financial Officer Analysts Neil Carnahan - Stifel John Newman - Canaccord Yale Jen - L… read more...

Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:10:50:000

Aldeyra Therapeutics, Inc. (ALDX) Q1 2018 Earnings Conference Call May 15, 2018 8:00 AM ET Executives Todd Brady - Chief Executive Officer of Aldeyra Therapeutics Steve Tulipano - Chief Financial Officer Analysts Neil Carnahan - Stifel John Newman - Canaccord Yale Jen - L… read more...

Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:10:50:000

Aldeyra Therapeutics, Inc. (ALDX) Q1 2018 Earnings Conference Call May 15, 2018 8:00 AM ET Executives Todd Brady - Chief Executive Officer of Aldeyra Therapeutics Steve Tulipano - Chief Financial Officer Analysts Neil Carnahan - Stifel John Newman - Canaccord Yale Jen - L… read more...

Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:10:50:000

Aldeyra Therapeutics, Inc. (ALDX) Q1 2018 Earnings Conference Call May 15, 2018 8:00 AM ET Executives Todd Brady - Chief Executive Officer of Aldeyra Therapeutics Steve Tulipano - Chief Financial Officer Analysts Neil Carnahan - Stifel John Newman - Canaccord Yale Jen - L… read more...

Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:10:50:000

Aldeyra Therapeutics, Inc. (ALDX) Q1 2018 Earnings Conference Call May 15, 2018 8:00 AM ET Executives Todd Brady - Chief Executive Officer of Aldeyra Therapeutics Steve Tulipano - Chief Financial Officer Analysts Neil Carnahan - Stifel John Newman - Canaccord Yale Jen - L… read more...

Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:10:50:000

Aldeyra Therapeutics, Inc. (ALDX) Q1 2018 Earnings Conference Call May 15, 2018 8:00 AM ET Executives Todd Brady - Chief Executive Officer of Aldeyra Therapeutics Steve Tulipano - Chief Financial Officer Analysts Neil Carnahan - Stifel John Newman - Canaccord Yale Jen - L… read more...

Aldeyra Therapeutics Announces First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-15 07:30:00:000

LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for … read more...

Aldeyra Therapeutics Announces First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-15 07:30:00:000

LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for … read more...

Aldeyra Therapeutics Announces First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-15 07:30:00:000

LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for … read more...

Aldeyra Therapeutics Announces First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-15 07:30:00:000

LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for … read more...

Aldeyra Therapeutics Announces First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-15 07:30:00:000

LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for … read more...

Aldeyra Therapeutics Announces First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-15 07:30:00:000

LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for … read more...

Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy

via: PR Newswire at 2018-05-10 08:00:00:000

LEXINGTON, Mass. , May 10, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced the hiring of David McMullin to… read more...

Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy

via: PR Newswire at 2018-05-10 08:00:00:000

LEXINGTON, Mass. , May 10, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced the hiring of David McMullin to… read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-09 08:00:00:000

LEXINGTON, Mass. , May 9, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will issue financial results for the quarter… read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-09 08:00:00:000

LEXINGTON, Mass. , May 9, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will issue financial results for the quarter… read more...

Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting

via: PR Newswire at 2018-05-01 07:00:00:000

LEXINGTON, Mass. , May 1, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, presented the results of a randomized, doubl… read more...

Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting

via: PR Newswire at 2018-05-01 07:00:00:000

LEXINGTON, Mass. , May 1, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, presented the results of a randomized, doubl… read more...

2 Small Biotechs To Consider

via: SeekingAlpha at 2018-04-27 10:50:42:000

If a man isn't willing to take some risk for his opinions, either his opinions are no good or he's no good Ezra Pound Today, we look at two developmental biotech concerns that seem to be offering attractive risk/reward profiles at current trading levels. Company Overv… read more...

2 Small Biotechs To Consider

via: SeekingAlpha at 2018-04-27 10:50:42:000

If a man isn't willing to take some risk for his opinions, either his opinions are no good or he's no good Ezra Pound Today, we look at two developmental biotech concerns that seem to be offering attractive risk/reward profiles at current trading levels. Company Overv… read more...

Your Daily Pharma Scoop: Alder's Migraine Data, Centene Revenues, Tesaro's Positive Results

via: SeekingAlpha at 2018-04-25 08:00:00:000

Analysis focus: Alder Biopharmaceuticals In mid-2017, despite seeing success in PROMISE 1, a phase 3 trial assessing Alder Biopharmaceuticals' (ALDR) eptinezumab targeting episodic migraine, the stock plummetted sharply. Investors were apparently not happy with the way the drug barely manage… read more...

Your Daily Pharma Scoop: Alder's Migraine Data, Centene Revenues, Tesaro's Positive Results

via: SeekingAlpha at 2018-04-25 08:00:00:000

Analysis focus: Alder Biopharmaceuticals In mid-2017, despite seeing success in PROMISE 1, a phase 3 trial assessing Alder Biopharmaceuticals' (ALDR) eptinezumab targeting episodic migraine, the stock plummetted sharply. Investors were apparently not happy with the way the drug barely manage… read more...

Late-stage study underway for Aldeyra's allergic conjunctivitis med reproxalap; shares up 2%

via: SeekingAlpha at 2018-04-24 10:06:44:000

The first patient has been enrolled in a Phase 3 clinical trial evaluating Aldeyra Therapeutics' ( ALDX +2.1% ) reproxalap for the treatment of allergic conjunctivitis. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Late-stage study underway for Aldeyra's allergic conjunctivitis med reproxalap; shares up 2%

via: SeekingAlpha at 2018-04-24 10:06:44:000

The first patient has been enrolled in a Phase 3 clinical trial evaluating Aldeyra Therapeutics' ( ALDX +2.1% ) reproxalap for the treatment of allergic conjunctivitis. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial

via: PR Newswire at 2018-04-24 08:00:00:000

LEXINGTON, Mass. , April 24, 2018 /PRNewswire/-- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has enrolled the fir… read more...

Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial

via: PR Newswire at 2018-04-24 08:00:00:000

LEXINGTON, Mass. , April 24, 2018 /PRNewswire/-- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has enrolled the fir… read more...

Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-03-29 14:59:02:000

Executives Dr. Todd Brady - Chief Executive Officer of Aldeyra Therapeutics Steve Tulipano - Chief Financial Officer Analysts Neil Carnahan - Stifel John Newman - Canaccord Yale Jen - Laidlaw & Company Elemer Piros - Cantor Corey Davis - Seaport Presentation Oper… read more...

Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-03-29 14:59:02:000

Executives Dr. Todd Brady - Chief Executive Officer of Aldeyra Therapeutics Steve Tulipano - Chief Financial Officer Analysts Neil Carnahan - Stifel John Newman - Canaccord Yale Jen - Laidlaw & Company Elemer Piros - Cantor Corey Davis - Seaport Presentation Oper… read more...

What's Next For Aldeyra Therapeutics?

via: SeekingAlpha at 2018-02-02 13:10:04:000

"Every man I meet wants to protect me. I can't figure out what from." - Mae West Today we revisit Aldeyra Therapeutics ( ALDX ). This is a " Tier 4 " Busted IPO we have not covered in some time. Company Overview Aldeyra Therapeuticsis an Lexington, Massachusetts based clinical stag… read more...

What's Next For Aldeyra Therapeutics?

via: SeekingAlpha at 2018-02-02 13:10:04:000

"Every man I meet wants to protect me. I can't figure out what from." - Mae West Today we revisit Aldeyra Therapeutics ( ALDX ). This is a " Tier 4 " Busted IPO we have not covered in some time. Company Overview Aldeyra Therapeuticsis an Lexington, Massachusetts based clinical stag… read more...

What's Next For Aldeyra Therapeutics?

via: SeekingAlpha at 2018-02-02 13:10:04:000

"Every man I meet wants to protect me. I can't figure out what from." - Mae West Today we revisit Aldeyra Therapeutics ( ALDX ). This is a " Tier 4 " Busted IPO we have not covered in some time. Company Overview Aldeyra Therapeuticsis an Lexington, Massachusetts based clinical stag… read more...

What's Next For Aldeyra Therapeutics?

via: SeekingAlpha at 2018-02-02 13:10:04:000

"Every man I meet wants to protect me. I can't figure out what from." - Mae West Today we revisit Aldeyra Therapeutics ( ALDX ). This is a " Tier 4 " Busted IPO we have not covered in some time. Company Overview Aldeyra Therapeuticsis an Lexington, Massachusetts based clinical stag… read more...

What's Next For Aldeyra Therapeutics?

via: SeekingAlpha at 2018-02-02 13:10:04:000

"Every man I meet wants to protect me. I can't figure out what from." - Mae West Today we revisit Aldeyra Therapeutics ( ALDX ). This is a " Tier 4 " Busted IPO we have not covered in some time. Company Overview Aldeyra Therapeuticsis an Lexington, Massachusetts based clinical stag… read more...

Your Daily Pharma Scoop: Achaogen Update, Seattle Genetics Acquires Cascadian, Vical Announces Restructuring

via: SeekingAlpha at 2018-02-01 08:00:00:000

Market update : Good morning, fellow investors. After the 21% gains last year, NBI kicked off the New Year on a very positive note. On the final trading day of the first month of 2018, the index is already up more than 9%. The gains have been partly driven by strong performance in the broader… read more...

Your Daily Pharma Scoop: Achaogen Update, Seattle Genetics Acquires Cascadian, Vical Announces Restructuring

via: SeekingAlpha at 2018-02-01 08:00:00:000

Market update : Good morning, fellow investors. After the 21% gains last year, NBI kicked off the New Year on a very positive note. On the final trading day of the first month of 2018, the index is already up more than 9%. The gains have been partly driven by strong performance in the broader… read more...

Your Daily Pharma Scoop: Achaogen Update, Seattle Genetics Acquires Cascadian, Vical Announces Restructuring

via: SeekingAlpha at 2018-02-01 08:00:00:000

Market update : Good morning, fellow investors. After the 21% gains last year, NBI kicked off the New Year on a very positive note. On the final trading day of the first month of 2018, the index is already up more than 9%. The gains have been partly driven by strong performance in the broader… read more...

Mid-stage study underway for Aldeyra's reproxalap in dry eye disease

via: SeekingAlpha at 2018-01-30 13:28:54:000

The first patient has been enrolled in a Phase 2b clinical trial assessing Aldeyra Therapeutics' ( ALDX -0.7% ) lead candidate reproxalap for the topical treatment of dry eye disease (DED). More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Read more … read more...

Mid-stage study underway for Aldeyra's reproxalap in dry eye disease

via: SeekingAlpha at 2018-01-30 13:28:54:000

The first patient has been enrolled in a Phase 2b clinical trial assessing Aldeyra Therapeutics' ( ALDX -0.7% ) lead candidate reproxalap for the topical treatment of dry eye disease (DED). More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Read more … read more...

Mid-stage study underway for Aldeyra's reproxalap in dry eye disease

via: SeekingAlpha at 2018-01-30 13:28:54:000

The first patient has been enrolled in a Phase 2b clinical trial assessing Aldeyra Therapeutics' ( ALDX -0.7% ) lead candidate reproxalap for the topical treatment of dry eye disease (DED). More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Read more … read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial

via: PR Newswire at 2018-01-30 08:00:00:000

LEXINGTON, Mass. , Jan. 30, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation and inborn errors of metabolism, today announced that it has enrolled the first patient in a Phase 2b clinic… read more...

Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial

via: PR Newswire at 2018-01-30 08:00:00:000

LEXINGTON, Mass. , Jan. 30, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation and inborn errors of metabolism, today announced that it has enrolled the first patient in a Phase 2b clinic… read more...

Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial

via: PR Newswire at 2018-01-30 08:00:00:000

LEXINGTON, Mass. , Jan. 30, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation and inborn errors of metabolism, today announced that it has enrolled the first patient in a Phase 2b clinic… read more...

Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy

via: SeekingAlpha at 2018-01-27 05:43:10:000

Shares of Aldeyra Therapeutics ( ALDX ) have finished just barely in the green since my initial article in which I noted that the company was transitioning into a promising late-stage story. This was followed by a "Buy the Secondary" piece , in which I outlined five reasons why readers shou… read more...

Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy

via: SeekingAlpha at 2018-01-27 05:43:10:000

Shares of Aldeyra Therapeutics ( ALDX ) have finished just barely in the green since my initial article in which I noted that the company was transitioning into a promising late-stage story. This was followed by a "Buy the Secondary" piece , in which I outlined five reasons why readers shou… read more...

Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy

via: SeekingAlpha at 2018-01-27 05:43:10:000

Shares of Aldeyra Therapeutics ( ALDX ) have finished just barely in the green since my initial article in which I noted that the company was transitioning into a promising late-stage story. This was followed by a "Buy the Secondary" piece , in which I outlined five reasons why readers shou… read more...

Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy

via: SeekingAlpha at 2018-01-27 05:43:10:000

Shares of Aldeyra Therapeutics ( ALDX ) have finished just barely in the green since my initial article in which I noted that the company was transitioning into a promising late-stage story. This was followed by a "Buy the Secondary" piece , in which I outlined five reasons why readers shou… read more...

Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy

via: SeekingAlpha at 2018-01-27 05:43:10:000

Shares of Aldeyra Therapeutics ( ALDX ) have finished just barely in the green since my initial article in which I noted that the company was transitioning into a promising late-stage story. This was followed by a "Buy the Secondary" piece , in which I outlined five reasons why readers shou… read more...

Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy

via: SeekingAlpha at 2018-01-27 05:43:10:000

Shares of Aldeyra Therapeutics ( ALDX ) have finished just barely in the green since my initial article in which I noted that the company was transitioning into a promising late-stage story. This was followed by a "Buy the Secondary" piece , in which I outlined five reasons why readers shou… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Stocks to watch next week

via: SeekingAlpha at 2017-12-16 06:51:50:000

Subscription notice: You can automatically receive Stocks to Watch every week by following the SA Stocks to Watch account and setting email alerts on. More news on: The Coca-Cola Company, The Boeing Company, Delta Air Lines, Inc., Consumer stocks news, Financial stocks news, Tech stoc… read more...

Stocks to watch next week

via: SeekingAlpha at 2017-12-16 06:51:50:000

Subscription notice: You can automatically receive Stocks to Watch every week by following the SA Stocks to Watch account and setting email alerts on. More news on: The Coca-Cola Company, The Boeing Company, Delta Air Lines, Inc., Consumer stocks news, Financial stocks news, Tech stoc… read more...

Stocks to watch next week

via: SeekingAlpha at 2017-12-16 06:51:50:000

Subscription notice: You can automatically receive Stocks to Watch every week by following the SA Stocks to Watch account and setting email alerts on. More news on: The Coca-Cola Company, The Boeing Company, Delta Air Lines, Inc., Consumer stocks news, Financial stocks news, Tech stoc… read more...

Stocks to watch next week

via: SeekingAlpha at 2017-12-16 06:51:50:000

Subscription notice: You can automatically receive Stocks to Watch every week by following the SA Stocks to Watch account and setting email alerts on. More news on: The Coca-Cola Company, The Boeing Company, Delta Air Lines, Inc., Consumer stocks news, Financial stocks news, Tech stoc… read more...

Stocks to watch next week

via: SeekingAlpha at 2017-12-16 06:51:50:000

Subscription notice: You can automatically receive Stocks to Watch every week by following the SA Stocks to Watch account and setting email alerts on. More news on: The Coca-Cola Company, The Boeing Company, Delta Air Lines, Inc., Consumer stocks news, Financial stocks news, Tech stoc… read more...

Your Daily Pharma Scoop: Valeant's B+L In India, TXMD's NDA Resubmission, Melinta Makes An Acquisition

via: SeekingAlpha at 2017-11-30 08:28:28:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Valeant B+L This is a tidy little art… read more...

Your Daily Pharma Scoop: Valeant's B+L In India, TXMD's NDA Resubmission, Melinta Makes An Acquisition

via: SeekingAlpha at 2017-11-30 08:28:28:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Valeant B+L This is a tidy little art… read more...

Your Daily Pharma Scoop: Valeant's B+L In India, TXMD's NDA Resubmission, Melinta Makes An Acquisition

via: SeekingAlpha at 2017-11-30 08:28:28:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Valeant B+L This is a tidy little art… read more...

Your Daily Pharma Scoop: Valeant's B+L In India, TXMD's NDA Resubmission, Melinta Makes An Acquisition

via: SeekingAlpha at 2017-11-30 08:28:28:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Valeant B+L This is a tidy little art… read more...

Your Daily Pharma Scoop: Valeant's B+L In India, TXMD's NDA Resubmission, Melinta Makes An Acquisition

via: SeekingAlpha at 2017-11-30 08:28:28:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Valeant B+L This is a tidy little art… read more...

Aldeyra's ADX-102 on par with steroid eye drop in mid-stage uveitis study; shares down 2%

via: SeekingAlpha at 2017-11-29 10:28:33:000

New analyses of a Phase 2 clinical trial evaluating Aldeyra Therapeutics' ( ALDX -1.5% ) topical reproxalap (formerly ADX-102) in patients with noninfectious anterior uveitis showed it to be non-inferior (no worse than) to Pred Forte (prednisone acetate), a topical steroid for ophthal… read more...

Aldeyra's ADX-102 on par with steroid eye drop in mid-stage uveitis study; shares down 2%

via: SeekingAlpha at 2017-11-29 10:28:33:000

New analyses of a Phase 2 clinical trial evaluating Aldeyra Therapeutics' ( ALDX -1.5% ) topical reproxalap (formerly ADX-102) in patients with noninfectious anterior uveitis showed it to be non-inferior (no worse than) to Pred Forte (prednisone acetate), a topical steroid for ophthal… read more...

Aldeyra's ADX-102 on par with steroid eye drop in mid-stage uveitis study; shares down 2%

via: SeekingAlpha at 2017-11-29 10:28:33:000

New analyses of a Phase 2 clinical trial evaluating Aldeyra Therapeutics' ( ALDX -1.5% ) topical reproxalap (formerly ADX-102) in patients with noninfectious anterior uveitis showed it to be non-inferior (no worse than) to Pred Forte (prednisone acetate), a topical steroid for ophthal… read more...

Aldeyra's ADX-102 on par with steroid eye drop in mid-stage uveitis study; shares down 2%

via: SeekingAlpha at 2017-11-29 10:28:33:000

New analyses of a Phase 2 clinical trial evaluating Aldeyra Therapeutics' ( ALDX -1.5% ) topical reproxalap (formerly ADX-102) in patients with noninfectious anterior uveitis showed it to be non-inferior (no worse than) to Pred Forte (prednisone acetate), a topical steroid for ophthal… read more...

Aldeyra's ADX-102 on par with steroid eye drop in mid-stage uveitis study; shares down 2%

via: SeekingAlpha at 2017-11-29 10:28:33:000

New analyses of a Phase 2 clinical trial evaluating Aldeyra Therapeutics' ( ALDX -1.5% ) topical reproxalap (formerly ADX-102) in patients with noninfectious anterior uveitis showed it to be non-inferior (no worse than) to Pred Forte (prednisone acetate), a topical steroid for ophthal… read more...

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting

via: PR Newswire at 2017-11-29 08:00:00:000

LEXINGTON, Mass. , Nov. 29, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented new statistic… read more...

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting

via: PR Newswire at 2017-11-29 08:00:00:000

LEXINGTON, Mass. , Nov. 29, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented new statistic… read more...

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting

via: PR Newswire at 2017-11-29 08:00:00:000

LEXINGTON, Mass. , Nov. 29, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented new statistic… read more...

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting

via: PR Newswire at 2017-11-29 08:00:00:000

LEXINGTON, Mass. , Nov. 29, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented new statistic… read more...

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting

via: PR Newswire at 2017-11-29 08:00:00:000

LEXINGTON, Mass. , Nov. 29, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented new statistic… read more...

Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-11-09 11:00:55:000

Aldeyra Therapeutics, Inc. (ALDX) Q3 2017 Earnings Conference Call November 9, 2017 8:00 AM ET Executives Steve Tulipano Chief Financial Officer Todd Brady President and Chief Executive Officer Analysts Neil Carnahan Stifel Nicolaus Yale Jen &#x20… read more...

Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-11-09 11:00:55:000

Aldeyra Therapeutics, Inc. (ALDX) Q3 2017 Earnings Conference Call November 9, 2017 8:00 AM ET Executives Steve Tulipano Chief Financial Officer Todd Brady President and Chief Executive Officer Analysts Neil Carnahan Stifel Nicolaus Yale Jen &#x20… read more...

Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-11-09 11:00:55:000

Aldeyra Therapeutics, Inc. (ALDX) Q3 2017 Earnings Conference Call November 9, 2017 8:00 AM ET Executives Steve Tulipano Chief Financial Officer Todd Brady President and Chief Executive Officer Analysts Neil Carnahan Stifel Nicolaus Yale Jen &#x20… read more...

Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-11-09 11:00:55:000

Aldeyra Therapeutics, Inc. (ALDX) Q3 2017 Earnings Conference Call November 9, 2017 8:00 AM ET Executives Steve Tulipano Chief Financial Officer Todd Brady President and Chief Executive Officer Analysts Neil Carnahan Stifel Nicolaus Yale Jen &#x20… read more...

Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-11-09 11:00:55:000

Aldeyra Therapeutics, Inc. (ALDX) Q3 2017 Earnings Conference Call November 9, 2017 8:00 AM ET Executives Steve Tulipano Chief Financial Officer Todd Brady President and Chief Executive Officer Analysts Neil Carnahan Stifel Nicolaus Yale Jen &#x20… read more...

Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results

via: PR Newswire at 2017-11-09 07:30:00:000

LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to… read more...

Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results

via: PR Newswire at 2017-11-09 07:30:00:000

LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to… read more...

Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results

via: PR Newswire at 2017-11-09 07:30:00:000

LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to… read more...

Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results

via: PR Newswire at 2017-11-09 07:30:00:000

LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to… read more...

Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results

via: PR Newswire at 2017-11-09 07:30:00:000

LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to… read more...

Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference

via: PR Newswire at 2017-11-07 08:00:00:000

LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to… read more...

Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference

via: PR Newswire at 2017-11-07 08:00:00:000

LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to… read more...

Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference

via: PR Newswire at 2017-11-07 08:00:00:000

LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to… read more...

Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference

via: PR Newswire at 2017-11-07 08:00:00:000

LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to… read more...

Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference

via: PR Newswire at 2017-11-07 08:00:00:000

LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to… read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results

via: PR Newswire at 2017-11-02 08:00:00:000

LEXINGTON, Mass. , Nov.2, 2017 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it… read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results

via: PR Newswire at 2017-11-02 08:00:00:000

LEXINGTON, Mass. , Nov.2, 2017 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it… read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results

via: PR Newswire at 2017-11-02 08:00:00:000

LEXINGTON, Mass. , Nov.2, 2017 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it… read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results

via: PR Newswire at 2017-11-02 08:00:00:000

LEXINGTON, Mass. , Nov.2, 2017 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it… read more...

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results

via: PR Newswire at 2017-11-02 08:00:00:000

LEXINGTON, Mass. , Nov.2, 2017 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it… read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2017-10-25 09:19:03:000

MGNX +36% on entering into an exclusive global collaboration and license agreement withIncyte (NASDAQ: INCY )for MacroGenics MGA012. More news on: MacroGenics, Inc., Incyte Corporation, Capricor Therapeutics, Inc., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2017-10-25 09:19:03:000

MGNX +36% on entering into an exclusive global collaboration and license agreement withIncyte (NASDAQ: INCY )for MacroGenics MGA012. More news on: MacroGenics, Inc., Incyte Corporation, Capricor Therapeutics, Inc., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2017-10-25 09:19:03:000

MGNX +36% on entering into an exclusive global collaboration and license agreement withIncyte (NASDAQ: INCY )for MacroGenics MGA012. More news on: MacroGenics, Inc., Incyte Corporation, Capricor Therapeutics, Inc., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2017-10-25 09:19:03:000

MGNX +36% on entering into an exclusive global collaboration and license agreement withIncyte (NASDAQ: INCY )for MacroGenics MGA012. More news on: MacroGenics, Inc., Incyte Corporation, Capricor Therapeutics, Inc., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2017-10-25 09:19:03:000

MGNX +36% on entering into an exclusive global collaboration and license agreement withIncyte (NASDAQ: INCY )for MacroGenics MGA012. More news on: MacroGenics, Inc., Incyte Corporation, Capricor Therapeutics, Inc., Stocks on the move, Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX